211 related articles for article (PubMed ID: 27079164)
1. Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case-control study.
Martinez C; Katholing A; Folkerts K; Cohen AT
J Thromb Haemost; 2016 Jul; 14(7):1374-83. PubMed ID: 27079164
[TBL] [Abstract][Full Text] [Related]
2. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
Woodruff S; Feugère G; Abreu P; Heissler J; Ruiz MT; Jen F
J Thromb Thrombolysis; 2016 Nov; 42(4):494-504. PubMed ID: 27344439
[TBL] [Abstract][Full Text] [Related]
3. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.
De Stefano V; Ruggeri M; Cervantes F; Alvarez-Larrán A; Iurlo A; Randi ML; Elli E; Finazzi MC; Finazzi G; Zetterberg E; Vianelli N; Gaidano G; Rossi E; Betti S; Nichele I; Cattaneo D; Palova M; Ellis MH; Cacciola R; Tieghi A; Hernandez-Boluda JC; Pungolino E; Specchia G; Rapezzi D; Forcina A; Musolino C; Carobbio A; Griesshammer M; Sant'Antonio E; Vannucchi AM; Barbui T
Leukemia; 2016 Oct; 30(10):2032-2038. PubMed ID: 27113812
[TBL] [Abstract][Full Text] [Related]
4. Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
Wang W; Su Y; Wu C; Sun Y; Dai N; Chen W; Zhang J; Xu Y; Brindis RG; Xu D; Li J
BMC Cardiovasc Disord; 2020 Feb; 20(1):53. PubMed ID: 32013892
[TBL] [Abstract][Full Text] [Related]
5. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
6. Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study.
Martinez C; Wallenhorst C; Rietbrock S; Freedman B
J Am Heart Assoc; 2020 Jan; 9(2):e014376. PubMed ID: 31937194
[TBL] [Abstract][Full Text] [Related]
7. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
8. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
Middeldorp S; Prins MH; Hutten BA
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD001367. PubMed ID: 25092359
[TBL] [Abstract][Full Text] [Related]
9. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
Schulman S; Zondag M; Linkins L; Pasca S; Cheung YW; de Sancho M; Gallus A; Lecumberri R; Molnar S; Ageno W; Le Gal G; Falanga A; Hulegårdh E; Ranta S; Kamphuisen P; Debourdeau P; Rigamonti V; Ortel TL; Lee A
J Thromb Haemost; 2015 Jun; 13(6):1010-8. PubMed ID: 25851122
[TBL] [Abstract][Full Text] [Related]
10. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study.
Eischer L; Kammer M; Traby L; Kyrle PA; Eichinger S
J Thromb Haemost; 2017 Jul; 15(7):1368-1374. PubMed ID: 28407356
[TBL] [Abstract][Full Text] [Related]
11. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
[TBL] [Abstract][Full Text] [Related]
12. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism.
Tripodi A; Legnani C; Lemma L; Cosmi B; Palareti G; Chantarangkul V; Mannucci PM
J Thromb Thrombolysis; 2010 Aug; 30(2):215-9. PubMed ID: 20419336
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
14. Thirteen-year trend in the persistence with vitamin K antagonists for venous thromboembolism in the UK: a cohort study.
Martinez C; Katholing A; Folkerts K; Rietbrock S
Curr Med Res Opin; 2018 Nov; 34(11):1985-1990. PubMed ID: 29798688
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
16. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
Mai V; Bertoletti L; Cucherat M; Jardel S; Grange C; Provencher S; Lega JC
PLoS One; 2019; 14(4):e0214134. PubMed ID: 30933993
[TBL] [Abstract][Full Text] [Related]
17. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
den Exter PL; Hooijer J; van der Hulle T; van Oosten JP; Dekkers OM; Klok FA; Huisman MV
Thromb Haemost; 2017 Nov; 117(11):2163-2167. PubMed ID: 28981552
[TBL] [Abstract][Full Text] [Related]
18. Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Noel-Savina E; Sanchez O; Descourt R; André M; Leroyer C; Meyer G; Couturaud F
Thromb Res; 2015 Jan; 135(1):78-83. PubMed ID: 25466839
[TBL] [Abstract][Full Text] [Related]
19. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism.
Bryk AH; Piróg M; Plens K; Undas A
Vascul Pharmacol; 2016 Dec; 87():242-247. PubMed ID: 27865826
[TBL] [Abstract][Full Text] [Related]
20. Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
Kooistra HA; Gebel M; Sahin K; Lensing AW; Meijer K
Thromb Haemost; 2015 Nov; 114(6):1136-43. PubMed ID: 26224199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
